Anti-Thymidine Kinase 1 antibody [EPR3193]
| Name | Anti-Thymidine Kinase 1 antibody [EPR3193] |
|---|---|
| Supplier | Abcam |
| Catalog | ab76495 |
| Prices | $391.00 |
| Sizes | 100 µl |
| Host | Rabbit |
| Clonality | Monoclonal |
| Isotype | IgG |
| Clone | EPR3193 |
| Applications | ICC/IF ICC/IF WB IP IHC-P FC |
| Species Reactivities | Human |
| Antigen | Synthetic peptide (Human) |
| Description | Rabbit Monoclonal |
| Gene | TK1 |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
![Anti-Thymidine Kinase 1 antibody [EPR3193] (ab76495) at 1/50000 dilution + Molt-4 cell lysate at 10 µgSecondaryHRP labelled goat anti-rabbit at 1/1000 dilution](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_5/10775_WB%2520thy%2520kin.jpg)
Anti-Thymidine Kinase 1 antibody [EPR3193] (ab76495) at 1/50000 dilution + Molt-4 cell lysate at 10 µgSecondaryHRP labelled goat anti-rabbit at 1/1000 dilution
Immunohistochemical analysis of paraffin-embedded human tonsils using 1/100 ab76495
Overlay histogram showing HeLa cells stained with ab76495 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab76495, 1/50 dilution) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-rabbit IgG (H+L) (ab96899) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was rabbit IgG (monoclonal) (1µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.
Product References
Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. - Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.
Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH, Heo J, Cho M, Chen H, Angarita FA, Addison C, McCart JA, Bell JC, Kirn DH. Cancer Res. 2013 Feb 15;73(4):1265-75.
Early assessment of the efficacy of temozolomide chemotherapy in experimental - Early assessment of the efficacy of temozolomide chemotherapy in experimental
Viel T, Schelhaas S, Wagner S, Wachsmuth L, Schwegmann K, Kuhlmann M, Faber C, Kopka K, Schafers M, Jacobs AH. PLoS One. 2013 Jul 4;8(7):e67911.
Monitoring metabolic responses to chemotherapy in single cells and tumors using - Monitoring metabolic responses to chemotherapy in single cells and tumors using
O'Brien PJ, Lee M, Spilker ME, Zhang CC, Yan Z, Nichols TC, Li W, Johnson CH, Patti GJ, Siuzdak G. Cancer Metab. 2013 Jan 23;1(1):4.
Antitumor activity from antigen-specific CD8 T cells generated in vivo from - Antitumor activity from antigen-specific CD8 T cells generated in vivo from
Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A, Radu CG, Galic Z, Zack JA. Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):E1408-16. doi: